Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the leader in...
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10
SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel...